You are here

Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife

Award Information
Agency: Department of Agriculture
Branch: N/A
Contract: 2007-33610-18486
Agency Tracking Number: 2006-00528
Amount: $346,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
882 S. Matlack Street Suite 105
West Chester, PA 19382
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Jeffrey Mattis
 Sr. Vice President, Scientific Affairs
 (610) 738-7938
 jmattis@mtarget.com
Business Contact
 Koon Pak
Title: President and CEO
Phone: (610) 738-7938
Email: cpak@mtarget.com
Research Institution
N/A
Abstract

Oral immunization of wildlife and stray dogs with live vaccines is the only
effective method to control rabies in carnivore species worldwide. Because
adenoviruses replicate on mucosal surfaces, they represent excellent vectors
that can be administered both orally and intranasally. The nearly ideal vaccine
vector for immunization of carnivores against rabies would be the canine
adenovirus type 2 (CAV 2) virus. The CAV 2 vaccine is a very effective livemodified
vaccine which has an excellent safety record and which is being used
worldwide for the routine vaccination of dogs against both CAV 1 and CAV 2.
Although this vaccine is usually administered subcutaneously, it is also effective
when administered orally and may allow for limited animal to animal
transmission. Previous phase I efforts demonstrated the initial proof of concept
through successful construction and selection of CAV 2-RVG viruses followed by
evaluation of safety and protective activity in laboratory animals. In this Phase II
project we propose to continue evaluation of the vaccine candidate through
optimization of virus growth and production of a research viral seed (RVS) stock,
genetic and thermal stability studies, in vitro and in vivo safety studies, and safety
and efficacy studies in target animals. It is likely that CAV2-RVG will be
immunogenic by the oral route in target animals resulting protective immunity
against rabies. A key concern to be addressed in this project is the safety of the
recombinant virus in target and non-target animals.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government